Cyprotex becomes one of the founding companies of the Alliance for Human Relevant Science

Cyprotex has become one of the founding companies of a new collaboration entitled the Alliance for Human Relevant Science.  The vision of this Alliance is to promote the acceptance, and use of, tools and therapies focused on human biology to improve public health and safety.

There is a widely acknowledged problem that, in pharmaceutical research, translation from pre-clinical animal models to humans can be inaccurate as physiologically the species are very different. There is now a tremendous opportunity to bridge this translational gap with human relevant technologies potentially making drug development faster and safer.

On 8th February 2017, the Alliance for Human Relevant Science in the UK House of Commons was launched. Sir David Amess MP hosted the event, which was full to capacity with senior scientists and MPs. Cyprotex was joined by the additional founding companies: CN Bio Innovations, Kirkstall, Safer Medicines Trust and Dr Hadwen Trust where each of us spoke about our commitment to predictive and accurate in vitro human based models.

Cyprotex has invested heavily in R&D developing predictive human in vitro models of toxicity.  This has focused on developing of 2D and 3D models for human hepatotoxicity, cardiotoxicity, nephrotoxicity and neurotoxicity utilising a range of techniques and models.  The aim of this R&D has been to validate new systems and approaches which better predict human toxicity than the current approaches.  Therefore, the aims of the Alliance align perfectly with our research at Cyprotex, and, in unison, we will strive for the continued improvement of human relevant models, and for widespread adoption of these techniques within the industry..

Full details of the Alliance as well as information from our launch event can be found at:

This website is intended to assist industry participants, customers and employees to understand Cyprotex's global operations and ambitions.